Charles Ryan

Charles Ryan at the University of Minnesota is a leading prostate cancer clinical trialist who has contributed to pivotal studies of abiraterone, enzalutamide, and the innovative bipolar androgen therapy (BAT) approach in mCRPC. His work has explored the mechanisms of androgen receptor signaling and therapeutic manipulation in treatment-resistant prostate cancer. He has championed patient-centered clinical trial design in mCRPC and has contributed to NCI and ECOG cooperative group prostate cancer trials. He is a sought-after expert in androgen receptor biology and its clinical implications.